scholarly journals Presentation and Treatment of Aggressive, Triple-Negative Carcinosarcoma of the Breast

2021 ◽  
Author(s):  
Niels Vizgan ◽  
Tahereh Jokar ◽  
Ladan Enayati ◽  
Muhammad Salyana ◽  
Vladimir Gotlieb
Keyword(s):  
Triple Negative ◽  
Treatment Method ◽  
Aggressive Subtype ◽  
Breast Malignancies

Breast carcinosarcoma is an aggressive subtype of cancer that accounts for less than a percent of all breast malignancies. Carcinosarcoma is difficult to diagnose and treat. In the following, we present a case of breast carcinosarcoma with the treatment method.

scholarly journals The overview of modern approaches in treatment of triple negative breast cancer

2020 ◽  
Vol 7 (1) ◽  
pp. 55-65
Author(s):  
A. A. Kharitonova ◽  
I. A. Smirnova ◽  
M. V. Kiseleva
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Parp Inhibitors ◽  
Morphological Response ◽  
Chemotherapy Drugs ◽  
Treatment Regimens ◽  
Dose Dense ◽  
Platinum Preparations ◽  
Aggressive Subtype

By far the most aggressive subtype of breast cancer is triple negative cancer. The purpose of this review is to analyze current ideas about the pathogenesis, clinical characteristics of different subtypes of triple negative breast cancer, the nature of its metastasis, mechanisms of chemoresistance. The review presents the results of modern regimens of drug therapy of triple negative breast cancer according to the publications of domestic and foreign oncologists. On the basis of various clinical studies, the effectiveness of the use of anthracyclines, taxanes in the dose-dense regime, platinum preparations and other chemotherapy drugs for the treatment of triple-negative cancer has been shown. The presented treatment regimens allow to achieve a complete morphological response in 85% of patients, to increase the rates of relapse-free and overall survival, comparable with other subtypes of breast cancer. The review highlights the possibilities of modern targeted drugs-PARP inhibitors, chk1 inhibitors UCN‑01, immunotherapy possibilities for the treatment of this aggressive subtype of breast cancer.

Triple-Negative Breast Cancer: A Comparison of Race and Survival

2018 ◽  
Vol 84 (6) ◽  
pp. 881-888
Author(s):  
Matthew P. Doepker ◽  
Scott D. Holt ◽  
Martin W. Durkin ◽  
Christopher H. Chu ◽  
James M. Nottingham
Keyword(s):  
Breast Cancer ◽  
South Carolina ◽  
Black Women ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
White Women ◽  
Triple Negative ◽  
Early Stage ◽  
Breast Cancer Patients ◽  
Aggressive Subtype

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with a high prevalence in blacks. South Carolina demographically has a high percentage of blacks. This study examines survival and recurrence associated with TNBC in black and white women. A retrospective review of breast cancer patients within the Palmetto Health Cancer Registry was performed from 1999 to 2015. Patient demographics and tumor characteristics were collected and correlated with outcomes. Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) were analyzed. The total number of breast cancer patients in the registry was 1723 (1085—white and 638—black). The median follow-up was 48.4 months. The majority of cancers diagnosed in both cohorts were early stage (I, IIA, IIB, 93.4% vs 90.4% P = NS). We identified 332 patients with TNBC. Of those 332 patients, 144 (43.4%) were whites and 188 (56.6%) were blacks. Older age (P = 0.01), high-grade (P < 0.001), and black race (P < 0.001) were significantly associated with TNBC on multivariate analysis. Five- and 10-year OS was significantly worse in blacks with TNBC (P < 0.001). There was no difference in DSS or RFS between the two cohorts. TNBC disproportionately affects black women and is an aggressive subtype of breast cancer with limited treatment options compared with receptor-positive breast cancer. Black patients with TNBC in our study had statistically worse OS. These findings are similar to what has been reported in the literature and prompts further research in newer targeted therapies.

scholarly journals HDAC inhibitors induce proline dehydrogenase (POX) transcription and anti-apoptotic autophagy in triple negative breast cancer

2019 ◽  
Vol 51 (10) ◽  
pp. 1064-1070 ◽  
Author(s):  
Huan Fang ◽  
Guangshi Du ◽  
Qiuju Wu ◽  
Rong Liu ◽  
Ceshi Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Hdac Inhibitors ◽  
Vital Role ◽  
Proline Dehydrogenase ◽  
Proline Oxidase ◽  
Metabolism Pathway ◽  
Key Enzyme ◽  
Aggressive Subtype

Abstract Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with poor clinical outcomes and without effective targeted therapies. Numerous studies have suggested that HDAC inhibitors (TSA/SAHA) may be effective in TNBCs. Proline oxidase, also known as proline dehydrogenase (POX/PRODH), is a key enzyme in the proline metabolism pathway and plays a vital role in tumorigenesis. In this study, we found that HDAC inhibitors (TSA/SAHA) significantly increased POX expression and autophagy through activating AMPK. Depletion of POX decreased autophagy and increased apoptosis induced by HDAC inhibitors in TNBC cells. These results suggest that POX contributes to cell survival under chemotherapeutic stresses and might serve as a potential target for treatment of TNBC.

scholarly journals Frequency of triple negative breast cancer in referrals patients to an oncology radiotherapy section

2021 ◽  
Vol 6 (1) ◽  
pp. e09-e09
Author(s):  
Maedeh Barahman ◽  
Mohammad Bahadoram ◽  
Omid Madani Khoshbakh ◽  
Mohammad-Reza Mahmoudian-Sani
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Cross Sectional Study ◽  
Cost Of Treatment ◽  
Cross Sectional ◽  
Hormonal Receptors ◽  
The Status ◽  
The Cost ◽  
Breast Malignancies

Introduction: Breast cancer is the most common cancer in women and the first cause of cancer death in women. This tumor often has hormonal receptors. The absence of these hormonal receptors leads to inability to treat the normal hormonal methods correctly. Objectives: In the present study, frequency of triple negative breast cancer in referrals patients to all patients with breast cancer involvement was investigated. Patients and Methods: This cross-sectional study was performed on patients with breast cancer. Accordingly, all patients with breast cancer involvement who referred to Firoozgar hospital from 2016 Until 2019 were evaluated sensually. The extracted parameters included the age, the status of the hormonal receptors in terms of positive or negative, and the degree of tumor based on the pathology in the case. Results: In this study, 1840 patients were diagnosed with malignancies, of which 266 (14.5%) were infected with a variety of breast malignancies negative triple breast was 48 patients (20.6%). Mean and standard deviation of patients with triple negative malignancy were 47.63 ± 13.34 years. We also observed the stage of breast cancer, the second most common stage (23 patients and 47.9%), and the first stage with the lowest incidence (4 patients and 8.3%) among patients. Conclusion: Considering the increased use of chemotherapy in treating this type of malignancy and the high cost of treatment in these patients, this malignancy should be considered in order to identify the disease early in order to plan for proper health and reduce the cost of the treatment.

scholarly journals Metaplastic Carcinoma of the Breast with Squamous Differentiation: A Case Report from the University Teaching Hospital of Kigali (CHUK), Rwanda

2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
Delphine Uwamariya ◽  
Carine Nyampinga ◽  
Anne Yvette Nsenguwera ◽  
Belson Rugwizangoga
Keyword(s):  
Triple Negative ◽  
Large Mass ◽  
University Teaching ◽  
Metaplastic Carcinoma ◽  
Squamous Cells ◽  
Spindle Cells ◽  
The University ◽  
Neoplastic Epithelium ◽  
Metaplastic Breast Carcinoma ◽  
Breast Malignancies

Metaplastic breast carcinoma is a rare and aggressive condition, accounting less than 1% of breast malignancies. It presents with large mass and frequently with distant metastasis at time of diagnosis. Morphologically, it is characterized by the differentiation of neoplastic epithelium into epithelial or mesenchymal-looking elements like squamous cells, spindle cells, cartilage, or bone and has poor prognosis with its triple negative status.

Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer

2012 ◽  
Vol 135 (2) ◽  
pp. 481-493 ◽  
Author(s):  
Johanna Tuomela ◽  
Jouko Sandholm ◽  
Peeter Karihtala ◽  
Joanna Ilvesaro ◽  
Katri S. Vuopala ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Tlr9 Expression ◽  
Aggressive Subtype

scholarly journals Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer

2021 ◽  
pp. 931-937
Author(s):  
Elan Gorshein ◽  
Kant Matsuda ◽  
Gregory Riedlinger ◽  
Levi Sokol ◽  
Lorna Rodriguez-Rodriguez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Metaplastic Breast Cancer ◽  
Durable Response ◽  
Disease Response ◽  
Molecular Abnormalities ◽  
Cancer Tumor ◽  
Resistance To Chemotherapy ◽  
Aggressive Subtype

Metaplastic breast cancer (MBC) is a rare and aggressive subtype of breast cancer. Tumor characteristics typically feature estrogen receptor, progesterone receptor, and HER2-negative, triple-negative breast cancer (TNBC), with a poorer prognosis relative to pure invasive ductal or lobular disease. Resistance to chemotherapy often leads to local recurrence and distant metastasis. Genomic profiling has identified multiple molecular abnormalities that may translate to targetable therapies in MBC. These tumors are known to display higher PD-L1 expressivity than other subtypes of breast cancer, and disease control with pembrolizumab and chemotherapy has been documented. We identify a patient with metastatic, metaplastic TNBC, with mesenchymal components and osseous differentiation, who completed 2 years of pembrolizumab treatment and has remained without evidence of disease after 32 months of observation, while maintaining good quality of life. Future efforts should focus on immunotherapy response with respect to the various subtypes of MBC, and treatment should continue to be incorporated in clinical trials to maximize disease response.

scholarly journals A review of current progress in triple-negative breast cancer therapy

Open Medicine ◽  
2020 ◽  
Vol 15 (1) ◽  
pp. 1143-1149
Author(s):  
Meiying Shen ◽  
Huawen Pan ◽  
Yuxia Chen ◽  
Yu Hang Xu ◽  
Weixiong Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Poor Prognosis ◽  
Triple Negative ◽  
Brca Mutation ◽  
Complete Response ◽  
Parp Inhibitors ◽  
The Past ◽  
Germline Brca Mutation ◽  
Aggressive Subtype

AbstractTriple-negative breast cancer (TNBC) is a particularly aggressive subtype known for its extremely high drug resistance, progression, poor prognosis, and lack of clear therapeutic targets. Researchers are aiming to advance TNBC treatment worldwide. In the past 2–3 years, more positive results have emerged in the clinical research on TNBC treatment. Based on the results, several impressive drugs have been approved to benefit patients with TNBC, including the PARP inhibitors olaparib and talazoparib for germline BRCA mutation-associated breast cancer (gBRCAm-BC) and immunotherapy using the checkpoint inhibitor atezolizumab in combination with nab-paclitaxel for programmed cell death-ligand 1-positive (PD-L1+) advanced TNBC. Although neoadjuvant therapy has focused on combinations of systemic agents to optimize pathologically complete response, metastatic TNBC still has a poor prognosis. Innovative multidrug combination systemic therapies based on neoadjuvants and adjuvants have led to significant improvements in outcomes, particularly over the past decade.

scholarly journals Advances in Single-Cell Sequencing Technology and its Applications in Triple-Negative Breast Cancer

2021 ◽  
Author(s):  
Meng Li ◽  
Miaozhou Wang ◽  
Yanlin Xie ◽  
Tingting Yan ◽  
Yanfang Li
Keyword(s):  
Breast Cancer ◽  
Single Cell ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Current Knowledge ◽  
Resistance Mechanisms ◽  
Sequencing Technology ◽  
Single Cell Sequencing ◽  
Aggressive Subtype

Abstract Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and is mainly treated with chemotherapy-based combination therapy. In recent years, the increasing development of single-cell sequencing (SCS) has become one of the most promising technologies in the field of biotechnology. The study of the heterogeneity of TNBC tumor cells using SCS will expand our current knowledge of metastasis, drug resistance mechanisms, mutations, and cloning in these cells; this will further guide clinical chemotherapy, targeted therapy, and immunotherapy. Relevant studies shown that SCS exactly plays an important role in clinical diagnosis and treatment. To highlight the role of SCS in the study of TNBC, we elaborate on the progress of research and the applications of SCS in TNBC.

scholarly journals High and low molecular weight hyaluronic acid-coated gold nanobipyramids for photothermal therapy

RSC Advances ◽  
2018 ◽  
Vol 8 (16) ◽  
pp. 9023-9030 ◽  
Author(s):  
Shuang Zhao ◽  
Ying Tian ◽  
Wenfei Liu ◽  
Yunyan Su ◽  
Yunlei Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Molecular Weight ◽  
Hyaluronic Acid ◽  
Triple Negative Breast Cancer ◽  
Photothermal Therapy ◽  
Triple Negative ◽  
Low Molecular Weight ◽  
Gold Nanobipyramids ◽  
Aggressive Subtype

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Hyaluronic acid (HA) could bind CD44 receptors, which are overexpressed on the surface of TNBC cells. Upon 808 nm laser irradiation, the GBPs@HA showed high therapeutic efficacy in vivo.

Sign in / Sign up

Export Citation Format

Share Document